Dynatronics Faces Customer Concentration Amidst Competitive Medical Device Market

TL;DR

**DYNTQ's heavy customer concentration is a red flag; this stock is a risky bet given its smaller scale in a competitive medical device market.**

AI Summary

Dynatronics Corp. (DYNTQ) reported a fiscal year ending June 30, 2025, with two major customers accounting for 14.5% and 12.0% of total net sales, indicating significant customer concentration. This is a slight shift from fiscal year 2024, where three major customers each contributed 13.0%, 12.7%, and 12.7% of net sales. The company operates as a medical device manufacturer, designing, manufacturing, and selling products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training under brands like Bird & Cronin, Solaris, and Hausmann. No single product exceeded 10% of total revenues in fiscal years 2025 or 2024, with manufactured products representing approximately 98% of total product sales. Key risks include intense competition from larger, more established companies and reliance on intellectual property protection, including a patent on thermoelectric technology valid until February 2033 and combination traction/phototherapy technology until December 2026. The strategic outlook focuses on maintaining its market position through operational excellence and sustaining core strengths, aiming for stable revenue streams and continued stakeholder value.

Why It Matters

Dynatronics' significant customer concentration, with two customers representing 26.5% of fiscal 2025 net sales, poses a substantial risk for investors, as the loss of even one major client could severely impact revenue. For employees, this concentration could lead to job insecurity if key customer relationships deteriorate. Customers benefit from Dynatronics' specialized medical devices, but the company's smaller scale compared to larger competitors like those in the therapeutic device market, which include four large domestic manufacturers, could limit innovation or pricing power. The broader market sees Dynatronics as a niche player in a fragmented industry, where its ability to compete on 'trusted high-quality brands, on-time product delivery, and superior customer care' is crucial for survival against more resourced rivals.

Risk Assessment

Risk Level: high — The risk level is high due to significant customer concentration, with two major customers accounting for 14.5% and 12.0% of total net sales in fiscal year 2025. This means 26.5% of the company's revenue is tied to just two entities, making it highly vulnerable to changes in their purchasing decisions. Additionally, the company operates in a highly fragmented industry with 'numerous competitors of varying sizes,' including 'several large corporations' with 'greater resources available to them' than Dynatronics, intensifying competitive pressures.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the stability of Dynatronics' relationships with its top two customers, which represent 26.5% of fiscal 2025 net sales. Given the high customer concentration and intense competition from larger players, consider this a speculative investment with significant downside risk.

Key Numbers

• $0.6 million — aggregate market value of common stock held by non-affiliates (as of December 31, 2024, indicating a small market capitalization)
• 16,001,331 — shares of common stock outstanding (as of October 6, 2025)
• 14.5% — percentage of total net sales from one major customer (in fiscal year 2025, highlighting customer concentration)
• 12.0% — percentage of total net sales from a second major customer (in fiscal year 2025, further emphasizing customer concentration)
• 98% — percentage of total product sales from manufactured products (in fiscal years 2025 and 2024, excluding freight and other revenue)
• February 2033 — patent expiration date (for thermoelectric technology)
• December 2026 — patent expiration date (for combination traction/phototherapy technology)
• 10% — maximum revenue from a single product (no single product exceeded this in fiscal years 2025 or 2024)

Key Players & Entities

• Dynatronics Corp. (company) — registrant
• Bird & Cronin (company) — product brand
• Solaris (company) — product brand
• Hausmann (company) — product brand
• PROTEAM (company) — product brand
• Mammoth (company) — product brand
• SEC (regulator) — Securities and Exchange Commission
• FDA (regulator) — Food and Drug Administration
• FTC (regulator) — Federal Trade Commission
• Utah (company) — state of incorporation

FAQ

Risk Factors

• Customer Concentration [high — market]: The company faces significant risk due to customer concentration, with two major customers accounting for 14.5% and 12.0% of total net sales in fiscal year 2025. This is a slight shift from fiscal year 2024, where three major customers represented 13.0%, 12.7%, and 12.7% of net sales, indicating a persistent reliance on a few key clients.
• Intense Competition [medium — market]: Dynatronics operates in a highly competitive medical device market, facing pressure from larger, more established companies. This competitive landscape could impact market share and pricing power.
• Intellectual Property Expiration [medium — legal]: The company's reliance on intellectual property protection is a key risk, particularly with a patent for thermoelectric technology expiring in February 2033 and a patent for combination traction/phototherapy technology expiring in December 2026. The expiration of these patents could lead to increased competition.

Industry Context

Dynatronics operates in the competitive medical device industry, specifically focusing on products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. The market includes larger, established players, creating a challenging environment for smaller companies. Key trends likely involve the demand for innovative solutions in restorative health and pain management, alongside increasing regulatory scrutiny.

Regulatory Implications

As a medical device manufacturer, Dynatronics is subject to regulations governing product safety, efficacy, and manufacturing practices. Compliance with these regulations is crucial for market access and maintaining operational integrity. The company's reliance on intellectual property also means navigating patent laws and potential infringement issues.

What Investors Should Do

1. Monitor customer concentration risks
2. Assess competitive landscape and IP strategy
3. Evaluate operational excellence and revenue stability

Key Dates

• 2026-12-01: Combination traction/phototherapy technology patent expiration — This patent expiration could lead to increased competition for products utilizing this technology.
• 2033-02-01: Thermoelectric technology patent expiration — This patent expiration could expose the company to new competitors in the thermoelectric technology market.

Glossary

Medical Device Manufacturer

A company that designs, produces, and sells devices used in the diagnosis, treatment, or prevention of disease or medical conditions. (Dynatronics operates within this sector, focusing on products for physical therapy, rehabilitation, and pain management.)

Customer Concentration

A situation where a company derives a significant portion of its revenue from a small number of customers. (Dynatronics exhibits customer concentration, with two major customers representing a substantial percentage of its net sales, posing a risk if these customers are lost.)

Intellectual Property Protection

Legal rights granted to creators and owners of intellectual property, such as patents, trademarks, and copyrights, to protect their inventions and creations. (Dynatronics relies on patents for its technologies, and their expiration dates are critical to its competitive advantage.)

Year-Over-Year Comparison

The fiscal year 2025 reporting shows a slight shift in customer concentration compared to fiscal year 2024, with two major customers now accounting for 14.5% and 12.0% of net sales, down from three customers representing 13.0%, 12.7%, and 12.7% in the prior year. While the overall percentage of sales from manufactured products remains high at 98%, the company's strategic outlook continues to focus on maintaining market position through operational excellence and sustaining core strengths, aiming for stable revenue streams.

Filing Documents

• form10k.htm (10-K) — 1052KB
• exhibit19-1.htm (EX-19.1) — 39KB
• exhibit23-1.htm (EX-23.1) — 2KB
• exhibit31-1.htm (EX-31.1) — 10KB
• exhibit31-2.htm (EX-31.2) — 10KB
• exhibit32-1.htm (EX-32.1) — 3KB
• exhibit19-1x001.jpg (GRAPHIC) — 8KB
• 0001062993-25-016039.txt ( ) — 6398KB
• dynt-20250630.xsd (EX-101.SCH) — 57KB
• dynt-20250630_cal.xml (EX-101.CAL) — 48KB
• dynt-20250630_def.xml (EX-101.DEF) — 113KB
• dynt-20250630_lab.xml (EX-101.LAB) — 641KB
• dynt-20250630_pre.xml (EX-101.PRE) — 305KB
• form10k_htm.xml (XML) — 908KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 6 Item 1B. Unresolved Staff Comments 12 Item 1C. Cybersecurity 13 Item 2.

Properties

Properties 13 Item 3.

Legal Proceedings

Legal Proceedings 14 Item 4. Mine Safety Disclosures 14 PART II. Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 15 Item 6. [Reserved] 15 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 20 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 20 Item 9. Changes in Disagreements with Accountants on Accounting and Financial Disclosure 36 Item 9A.

Controls and Procedures

Controls and Procedures 36 Item 9B. Other Information 36 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 36 PART III. Item 10. Directors, Executive Officers and Corporate Governance 37 Item 11.

Executive Compensation

Executive Compensation 37 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 37 Item 13. Certain Relationships and Related Transactions, and Director Independence 37 Item 14. Principal Accounting Fees and Services 37 PART IV. Item 15. Exhibits, Financial Statement Schedules 38 Item 16. Form 10-K Summary 40

Signatures

Signatures 41 1 Cautionary Note Regarding Forward-Looking Statements This Annual Report on Form 10-K, including documents incorporated herein by reference, contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements include, but are not limited to: any projections of net sales, earnings, or outlook for fiscal year 2026, and other financial items; any statements of the strategies, plans and objectives of management for future operations; expectations in connection with the Company's previously announced business optimization plan; any statements concerning proposed new products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements can be identified by their use of such words as "may," "will," "estimate," "intend," "continue," "believe," "expect," or "anticipate" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could c

Business

Item 1. Business Company Background Dynatronics Corporation is a leading medical device company committed to providing high-quality products designed to accelerate optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin, Solaris, Hausmann, PROTEAM, and Mammoth, among others. Unless the context otherwise requires, all references in this report to "registrant," "we," "us," "our," "Dynatronics," or the "Company" refer to Dynatronics Corporation, a Utah corporation, and its wholly owned subsidiaries. In this report, unless otherwise expressly indicated, references to "dollars" and "

View Full Filing

View this 10-K filing on SEC EDGAR